Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2018 17:00 ET | Source: Novartis Pharma AG

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects...
September 12, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis survey shows psoriasis patients want treatment effect beyond clear skin

New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no...
September 11, 2018 01:00 ET | Source: Novartis Pharma AG

Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis

Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has...
September 11, 2018 01:00 ET | Source: Novartis Pharma AG

Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz

Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg...
September 11, 2018 01:00 ET | Source: Novartis Pharma AG

Alcon confirme son engagement envers la Suisse en perspective de la scission proposée avec Novartis

Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon...
September 05, 2018 22:30 ET | Source: Novartis Pharma AG

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic...
August 29, 2018 01:15 ET | Source: Novartis Pharma AG

European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma patients are...
August 29, 2018 01:00 ET | Source: Novartis Pharma AG

Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma

Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising...
August 27, 2018 02:00 ET | Source: Novartis Pharma AG

Novartis investiert in die Herstellung von Zell- und Gentherapien in Stein

Potentieller Aufbau von bis zu 450 neuen Positionen in den nächsten drei Jahren und gestaffelte Investitionen von bis zu CHF 90 Millionen Etablierung einer Plattform zur Herstellung von Zell-...
August 27, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission

Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein...